| Annesley Elizabeth Lord Beringer, PTA | |
|
118 Northport Ave, Belfast, ME 04915-6009 | |
| (207) 505-4833 | |
| Not Available |
| Full Name | Annesley Elizabeth Lord Beringer |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation - Pediatric Rehabilitation Medicine |
| Location | 118 Northport Ave, Belfast, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710612270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P0010X | Physical Medicine & Rehabilitation - Pediatric Rehabilitation Medicine | PA6101 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Annesley Elizabeth Lord Beringer, PTA 118 Northport Ave, Belfast, ME 04915-6009 Ph: () - | Annesley Elizabeth Lord Beringer, PTA 118 Northport Ave, Belfast, ME 04915-6009 Ph: (207) 505-4833 |
News Archive
Researchers have identified diagnostic microRNA panels in whole blood that had the ability to distinguish, to some degree, patients with and without pancreatic cancer, according to a study in the January 22/29 issue of JAMA.
Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme, the most malignant cancer of the brain.
SunLink Health Systems, Inc.(the "Company") today announced that in view of the unusual activity in the Company's stock, the New York Stock Exchange (NYSE) has contacted the Company in accordance with the NYSE's usual practice and requested that the Company respond by news release to the unusual activity.
John Niederhuber, a surgeon whom President Bush on Tuesday appointed as National Cancer Institute director, on Wednesday said that he hopes to find new nontoxic cancer medications but added that the agency likely will have to eliminate some programs because of budgetary issues, the New York Times reports.
› Verified 6 days ago